ArticleEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2025
Actions to mitigate ocular adverse events related to hair styling cosmetics in Brazil: a descriptive and correlational study (2022-2024).
Article in Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe health surveillance actions implemented by the Brazilian Health Regulatory Agency (ANVISA) to mitigate cases of ocular adverse events related to hair styling creams in Brazil and verify correlation between reported cases and these actions.
methodsThis is a descriptive and correlational study based on analysis of documents and the ANVISA case reporting database, between March 2022 and March 2024. Spearman's correlation coefficient was used to examine correlation between ANVISA actions and cases of adverse events (p-value<0.05).
resultsThree distinct periods were identified in relation to ANVISA actions (n=172) and reported cases (n=636). The second period (December 2022 to June 2023) presented the highest number of actions (n=125; 72.7%), coinciding with the peak of case reports (n=550). During this period, two safety alerts were published and a precautionary ban was ordered on all hair styling creams sold in Brazil, which lasted 38 days. In the third period (July 2023 to March 2024), the highest number of cream marketing cancellations occurred (n=3,122; 79.3%), and toxicology analyses indicated that six (30.0%) samples were classified as severely irritant/corrosive. There was a positive and strong correlation between the actions and the reported cases, ranging from 0.53 (p-value 0.006) to 0.74 (p-value<0.001).
conclusionThe strong positive correlation demonstrates that ANVISA's actions were reactive to the increase in case reports, reinforcing the importance of active surveillance and rapid interventions to control risks to public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.